The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
== Incumbents == Lord Lieutenant of Anglesey – Henry Paget Lord Lieutenant of Brecknockshire and Monmouthshire – Henry Somerset, 6th Duke of Beaufort Lord Lieutenant of Caernarvonshire – Thomas Bulkeley, 7th Viscount Bulkeley Lord Lieutenant of Cardiganshire – Thomas Johnes Lord Lieutenant of Carmarthenshire – George Rice, 3rd Baron Dynevor Lord Lieutenant of Denbighshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Flintshire – Robert Grosvenor, 1st Marquess of Westminster Lord Lieutenant of Glamorgan – John Stuart, 1st Marquess of Bute Lord Lieutenant of Merionethshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Montgomeryshire – Edward Clive, 1st Earl of Powis Lord Lieutenant of Pembrokeshire – Richard Philipps, 1st Baron Milford Lord Lieutenant of Radnorshire – George Rodney, 3rd Baron Rodney Bishop of Bangor – William Cleaver (until 25 November) Bishop of Llandaff – Richard Watson Bishop of St Asaph – Samuel Horsley (until 4 October); William Cleaver (from 25 November) Bishop of St Davids – Thomas Burgess
Hayley Clay (Kiernan Shipka) is Whitney Halberstram’s executive assistant at Tender. Recruited from an escort agency, she previously serviced wealthy clients to obtain compromising material, including an emir connected to Al-Mi’raj, Pierpoint's new owner. While at Tender, she spends a night with James Dycker, a financial journalist investigating the company, and later learns his identity. Before leaving her apartment, Dycker urges her to question the circumstances of her predecessor’s departure. Hayley asks Whitney directly; he claims the former assistant suffered from Crohn’s disease and that he privately funded her treatment. After Henry Muck becomes CEO, Hayley also serves as his assistant, and during a business trip to Vienna, Yasmin arranges a threesome involving Henry and Hayley. As Dycker continues probing Tender’s laundering of illegal payments, Hayley files a sexual assault complaint against him. Combined with an article arranged by Yasmin alleging Dycker colluded with short sellers, the accusation leads to his dismissal. Whitney promotes Yasmin to head of communications, and Yasmin elevates Hayley to a senior communications role. Following reports exposing Tender’s fraudulent African profits, Hayley reviews Whitney’s emails and discovers her predecessor also came from the same escort agency. She resigns, confronting Whitney over employing her underage cousin Dolly to seduce Eric Tao. Hayley then approaches Yasmin, revealing that their threesome was recorded and that she is an escort, seeking leverage within British high society.
== Outlook == Up to 40% of children with SJIA have a monocyclic disease history and recover entirely after a variable time. A small percentage of children experience a polycyclic course of the illness, which is marked by recurrent bouts of active illness interspersed with medication-free remission periods. Over half of the children with sJIA have a prolonged disease course, according to studies conducted over the previous 30 years.
Sources: en.wikipedia.org
After he teaches them to bark on all fours to fend off cats, the family holds a memorial service for the brother. Christina again barters for oral sex from the elder daughter. The daughter rejects her offer of hair gel and demands the Hollywood VHS tapes in her bag. She watches the films (Rocky IV and Jaws) in secret and afterwards recreates scenes and quotes their dialogue. When the father discovers the tapes, he beats her with one of them, then goes to Christina's flat and hits her with her VCR, cursing her future children to be corrupted by "bad influences". The parents decide that, with Christina no longer available, they will have the son choose one of his sisters as a new sexual partner. After fondling both sisters with his eyes closed, he chooses the elder. She is uncomfortable during their sex and afterwards threatens her brother in the style of Hollywood film dialogues. During a performance for the parents' wedding anniversary, the younger daughter stops to rest, but the elder continues and dances the choreography from Flashdance, disturbing her parents. That night, she knocks out one of her dogteeth with a dumbbell and hides in the boot of her father's car. The father discovers her tooth fragments and searches for her fruitlessly. He drives to work the next day; the car sits outside the factory, unattended.
=== Peroxisomes receptor agonists === An important regulator in bile acid homeostasis is the alpha and delta isoforms of the peroxisome proliferator-activated receptor (PPARα, PPARδ). The function of PPARα is that it promotes bile acid excretion and lowers inflammation by acting on nuclear transcription factors. A well known agonist are fibrates and in the clinical trials, there was a significant biochemical response in most patients. A combination therapy with bezafibrate showed remarkable biochemical improvement, with 67% of patients normalizing their alkaline phosphatase levels. Another study of 48 patients with PBC found a combination of bezafibrate and UDCA showed a decrease of alkaline phosphatase in all patients. Further, the study found those treated had a marked relief in pruritus. However, fibrates are associated with a number of adverse effects including arthritis, leg edema, polydipsia, and myalgias. Elevations of creatinine and creatine phosphokinase were also found over a long term use.
In 1959, Nikita Khrushchev launched an anti-religious campaign. Of the 50 churches that were operating in Moscow in 1959, 30 were closed and six demolished. On 8 May 1965, the 20th anniversary of the Soviet victory in World War II, Moscow was awarded the honorary title of Hero City. The Moscow Ring Road (MKAD) was opened in 1961. It had four lanes running 109 kilometers (68 mi) along city borders. The MKAD marked the administrative boundaries of the city until the 1980s, when outlying suburbs beyond the ring road were incorporated. In 1980, Moscow hosted the Summer Olympic Games, which were boycotted by the United States and other Western countries because the Soviet Union invaded Afghanistan in 1979. In 1991, Moscow was the scene of a coup attempt by conservative communists opposed to the liberal reforms of Mikhail Gorbachev.
=== Exercise and muscle soreness === A 2017 review showed that taking antioxidant dietary supplements before or after exercise is unlikely to produce a noticeable reduction in muscle soreness after a person exercises.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.